ASH 2023

Important data on transplant-eligible NDMM

Update on transplant-ineligible NDMM

Practice changing - Daratumumab before und after transplantation

Quatruplet therapy - the new standard in induction & consolidation in NDMM

Isa-KRd - practice changing?

CD38 antibodies - good in 1st line but bad in 2nd line?

Daratumumab vor und nach Transplantation neuer Standard

Vierfachkombinationen - der neue Standard bei Induktion und Erhaltung

Isa-KRd - practice changing?

CD38-antistoffer - bra i førstelinje men ikke i andrelinje?

The future of CAR T Cell treatment - I

The future of CAR T Cell treatment - II

Bispecific antibodies - update and outlook on treatment strategies

cilta-cel in early lines

New data on efficacy and safety of CAR T cells and bispecifics/TCEs

Survival data from KarMMa-3

Early data on TriTac

Response predictors in immunotherapy

Single-cell analysis of CAR T cells

Overlevelsesdata fra KarMMa-3

cilta-cel in frühen Linien

Einzelzell-Analysen bei CAR-T-Zellen

CAR-T-Zellen und bispezifische Antikörper/TCEs: Neue Daten zu Wirksamkeit und Sicherheit

Are we ready for screening?

Are we preventing myeloma yet?

CENTAURUS: using single-drug Daratumumab in smoldering myeloma

First whole genome sequencing trial with long-term FUP in SMM treated with KRd/R maintenance

CENTAURUS: using single-drug Daratumumab in smoldering myeloma

First whole genome sequencing trial with long-term FUP in SMM treated with KRd/R maintenance

Updates for immunotherapy of follicular lymphoma

Bispecific antibodies in follicular lymphoma (1st line)

Real-world data of CAR T in relapsed follicular lymphoma

Long-term follow-up of ELARA study

CAR T cells in follicular lymphoma (1st relapse)

Chemo-free combination for 1st line follicular lymphoma

Cost-effectiveness analysis of Mosunetuzumab and CAR T in R/R follicular lymphoma

Analisi costo-beneficio di mosunetuzumab vs CART nel linfoma follicolare recidivato refrattario

Data "real world" delle CART nel linfoma follicolare recidivato refrattario

Follow-up a lungo termine dello studio ELARA

Una combinazione chemo-free per la prima linea del linfoma follicolare

Bispezifische Antikörper im follikulären Lymphom (1st line)

CAR-T-Zellen im follikulären Lymphom (erstes Rezidiv)

No efficacy of vitamin D in rituximab therapy

Keine Wirksamkeit von Vitamin D bei Rituximab-Therapie

New data for MCL - part I

New data for MCL - part II

The SYMPATICO study confirms the synergy between ibrutinib and venetoclax in rel/ref MCL

Sobering results for bendamustine and venotoclax in MCL (1st line)

BOVEN: An effective MRD-guided strategy free of chemo for untreated TP53-mutated MCL

Ibrutinib plus Venetoclax in R/R MCL - a new treatment option!

Sequential use of R-bendamustine and ibrutinib?

A new standard for R/R MCL?

Adding Ara-C and lenalidomide to the standard RCHOP+RM did not improve survival in older patients

Is obinutuzumab superior to rituximab in MCL?

Venetoclax added to RBAC significantly improves PFS in older patients with high-risk MCL

TP53-mutant MCL - a new standard in 1st line?

Venetoclax mejora significativamente la PFS de RBAC en mayores con LCM de alto riesgo

Ny standardbehandling för recidiv av MCL?

El estudio SYMPATICO confirma la sinergia entre ibrutinib y venetoclax en el LCM rec/ref

Ernüchternde Ergebnisse für Bendamustin und Venotoclax beim MCL 1st line

BOVEN: Una estrategia sin quimio guiada por EMR, altamente eficaz en el LCM con mutaciones de TP53

Vilken CD20-antikropp är att föredra vid MCL?

Sekventiell eller samtidig behandling med R-bendamustin och ibrutinib?

Añadir Ara-C y lenalidomida al estándar RCHOP+MR no mejora la supervivencia en pacientes mayores

Ibrutinib plus Venetoclax beim rezidivierenden MCL - eine neue Therapieoption!

MCL mit TP53-Mutation: Neuer Standard in der Erstlinie?

Highlights in chronic lymphocytic leukemia

Pirtobrutinib in relapsed CLL

Sonrotoclax plus zanubrutinib in 1st line CLL

Ibrutinib plus venetoclax as MRD-guided treatment

Bv-AVD in older patients

Nivo-AVD bei älteren Patienten besser als Bv-AVD

DLBCL - new treatment approaches and diagnostic procedures